The EDF Guidelines give the highest recommendation for fixed dose combinations of benzoyl peroxide (BPO) + clindamycin (Duac) or BPO + adaplene as first-line therapy in mild to moderate acne. 1 In a 12-weeks study of 148 patients Duac 5% helped patients to achieve treatment success faster than Zineryt (for inflammatory and for total lesions at week 2, p=0,029 and p=0,017). 2
The EDF Guidelines recommend against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance. Duac 5% is more effective than monotherapies in reducing inflammatory lesions, with comparable tolerability. 1
Duac is a registered trademark of the GlaxoSmithKline group of companies.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
March 2020: PM-GB-CBP-WCNT-200004 V2.0
Falsified Medicines Directive
Information to support UK healthcare professionals on the falsified medicines directive in relation to GSK medicines and vaccines.